Review
Year 2018,
Volume: 10 Issue: 1, 39 - 43, 21.01.2018
Abstract
Abstract
Osteoporosis is a metabolic bone disease characterized by decreased bone mineral density and increased bone fractures in body. Especially in children with chronic diseases there is an increased risc of osteoporosis. In pediatric osteoporotic patients, diagnosis and treatment is more different than adults.
Keywords
References
- Kaynaklar 1.N J Shaw. Arch Dis Child Educ Pract Ed 2007;92:ep169–ep175. doi: 10.1136/adc.2006.105791 2.Goulding A, Cannan R, Williams SM, et al. BMD in girls withforearm fractures. J Bone Miner Res 1998;13:143–8. 3.Clark EM, Ness AR, Bishop NJ, et al. Association between bonemass and fractures in children: a prospective cohort study. JBone Miner Res 2006;21:1489–95. 4.Allgrove J, Shaw NJ (eds): Calcium and Bone Disorders inChildren and Adolescents. 2nd, revised edition. Endocr Dev.Basel, Karger, 2015, vol 28, pp 176–195 (DOI: 10.1159/000381045) 5.Morello R, Bertin TK, Chen Y, et al. CRTAP is required forprolyl 3-hydroxylation and mutations cause recessive osteo-genesis imperfecta. Cell 2006;127:291–304. 6.Hartikka H, Makitie O, Mannikko M, et al. Heterozygous mu-tations in the LDL receptor related protein 5 (LRP5) gene areassociated with primary osteoporosis in children. J Bone Mi-ner Res 2005;20:783–9. 7.Gong Y, Slee RB, Fukai N, et al. LDL receptor-related pro-tein 5 (LRP5) affects bone accrual and eye development. Cell2001;107:513–23. 8.Mäkitie, O. Nat. Rev. Rheumatol. 9, 465–475 (2013); publis-hed online 16 April 2013; doi:10.1038/nrrheum.2013.45 9.Stevenson RD, Conaway M, Barrington JW, et al. Fracturerate in children with cerebral palsy. Pediatr Rehabil2006;9:396–403. 10.Binkley T, Johnson J, Vogel L, et al. Bone measurements byperipheral quantitative computed tomography(pQCT) inchildren with cerebral palsy. J Pediatr 2005;147:791–6. 11.Larson CM, Henderson RC. Bone mineral density and frac-tures in boys with Duchenne muscular dystrophy. J PediatrOrthop 2000;20:71–4. 12.Sylvester FA, Davis PM, Wyzga N, et al. Are activated T cellsregulators of bone metabolism in children with Crohn disea-se? J Pediatr 2006;148:461–6. 13.Thearle M, Horlick M, Bilezikian JP, et al. Osteoporosis: anunusual presentation of childhood Crohn’s disease. J Clin En-docrinol Metab 2000;85:2122–6. 14.Bielinski BK, Darbyshire PJ, Mathers L, et al. Impact of di-sordered puberty on bone density in b thalassaemia major. BrJ Haemat 2003;120:353–8. 15.Gafni R, Baron J. Overdiagnosis of osteoporosis in childrendue to misinterpretation of dual-energy X-ray absorptiometry(DEXA). J Pediatr 2004;144:253–7. 16.Homik J, Suarez-Almazor ME, Shea B, et al. Calcium and vi-tamin D for corticosteroid-induced osteoporosis. CochraneDatabase Syst Rev 2000;2:CD000952. 17.Caulton JM, Ward KA, Alsop CW, et al. A randomised con-trolled trial of standing programme on bone mineral densityin non-ambulant children with cerebral palsy. Arch Dis Child2004;89:131–5. 18.Ward K, Alsop C, Caulton J, et al. Low magnitude mechani-cal loading is osteogenic in children with disabling conditi-ons. J Bone Miner Res 2004;19:360–9 19.Glorieux FH, Bishop NJ, Plotkin H, et al. Cyclic administra-tion of pamidronate in children with severe osteogenesis im-perfecta. N Engl J Med 1998;339:947–52. 20.Grissom LE, Kecskemethy HH, Bachrach SJ, et al. Bone den-sitometry in pediatric patients treated with pamidronate. Pe-diatr Radiol 2005;35:511–17. 21.7 Sakkers R, Kok D, Engelbert R, et al. Skeletal effects andfunctional outcome with olpadronate in children with osteo-genesis imperfecta: a 2 year randomised placebo-controlledstudy. Lancet 2004;363:1427–31. 22.Grissom LE, Kecskemethy HH, Bachrach SJ, et al. Bone den-sitometry in pediatric patients treated with pamidronate. Pe-diatr Radiol 2005;35:511–17. 23.Munns CF, Rauch F, Zeitlin L, et al. Delayed osteotomy butnot fracture healing in pediatric osteogenesis imperfecta pa-tients receiving pamidronate. J Bone Miner Res2004;19:1779–86 24.Papapoulos SE, Cremers SCLM. Prolonged bisphosphonaterelease after treatment in children. N Engl J Med 2007;356:1075–76. 25.Ward KA, Adams JE, Freemont TJ, et al. Can bisphosphona-te treatment be stopped in a growing child with skeletal fra-gility? Osteoporos Int 2007;18:1137–40. 26.Bilezikian JP. Osteonecrosis of the jaw: do bisphosphonatespose a risk? N Engl J Med 2006;355:2278–81. 43 27.Whyte MP, Wenkert D, Clements KL, et al. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003;349:457–63.
Year 2018,
Volume: 10 Issue: 1, 39 - 43, 21.01.2018
Abstract
Öz
Osteoporoz kemik mineral yoğunluğunda azalma ve vücutta çeşitli kemiklerdekırık ile seyreden metabolik hastalıktır. Özellikle kronik hastalığı olan çocuklarda osteoporoza riski artmıştır. Çocuk hastalarda tanı ve tedavi izlemi yetişkinlerden farklılık göstermektedir.
Keywords
References
- Kaynaklar 1.N J Shaw. Arch Dis Child Educ Pract Ed 2007;92:ep169–ep175. doi: 10.1136/adc.2006.105791 2.Goulding A, Cannan R, Williams SM, et al. BMD in girls withforearm fractures. J Bone Miner Res 1998;13:143–8. 3.Clark EM, Ness AR, Bishop NJ, et al. Association between bonemass and fractures in children: a prospective cohort study. JBone Miner Res 2006;21:1489–95. 4.Allgrove J, Shaw NJ (eds): Calcium and Bone Disorders inChildren and Adolescents. 2nd, revised edition. Endocr Dev.Basel, Karger, 2015, vol 28, pp 176–195 (DOI: 10.1159/000381045) 5.Morello R, Bertin TK, Chen Y, et al. CRTAP is required forprolyl 3-hydroxylation and mutations cause recessive osteo-genesis imperfecta. Cell 2006;127:291–304. 6.Hartikka H, Makitie O, Mannikko M, et al. Heterozygous mu-tations in the LDL receptor related protein 5 (LRP5) gene areassociated with primary osteoporosis in children. J Bone Mi-ner Res 2005;20:783–9. 7.Gong Y, Slee RB, Fukai N, et al. LDL receptor-related pro-tein 5 (LRP5) affects bone accrual and eye development. Cell2001;107:513–23. 8.Mäkitie, O. Nat. Rev. Rheumatol. 9, 465–475 (2013); publis-hed online 16 April 2013; doi:10.1038/nrrheum.2013.45 9.Stevenson RD, Conaway M, Barrington JW, et al. Fracturerate in children with cerebral palsy. Pediatr Rehabil2006;9:396–403. 10.Binkley T, Johnson J, Vogel L, et al. Bone measurements byperipheral quantitative computed tomography(pQCT) inchildren with cerebral palsy. J Pediatr 2005;147:791–6. 11.Larson CM, Henderson RC. Bone mineral density and frac-tures in boys with Duchenne muscular dystrophy. J PediatrOrthop 2000;20:71–4. 12.Sylvester FA, Davis PM, Wyzga N, et al. Are activated T cellsregulators of bone metabolism in children with Crohn disea-se? J Pediatr 2006;148:461–6. 13.Thearle M, Horlick M, Bilezikian JP, et al. Osteoporosis: anunusual presentation of childhood Crohn’s disease. J Clin En-docrinol Metab 2000;85:2122–6. 14.Bielinski BK, Darbyshire PJ, Mathers L, et al. Impact of di-sordered puberty on bone density in b thalassaemia major. BrJ Haemat 2003;120:353–8. 15.Gafni R, Baron J. Overdiagnosis of osteoporosis in childrendue to misinterpretation of dual-energy X-ray absorptiometry(DEXA). J Pediatr 2004;144:253–7. 16.Homik J, Suarez-Almazor ME, Shea B, et al. Calcium and vi-tamin D for corticosteroid-induced osteoporosis. CochraneDatabase Syst Rev 2000;2:CD000952. 17.Caulton JM, Ward KA, Alsop CW, et al. A randomised con-trolled trial of standing programme on bone mineral densityin non-ambulant children with cerebral palsy. Arch Dis Child2004;89:131–5. 18.Ward K, Alsop C, Caulton J, et al. Low magnitude mechani-cal loading is osteogenic in children with disabling conditi-ons. J Bone Miner Res 2004;19:360–9 19.Glorieux FH, Bishop NJ, Plotkin H, et al. Cyclic administra-tion of pamidronate in children with severe osteogenesis im-perfecta. N Engl J Med 1998;339:947–52. 20.Grissom LE, Kecskemethy HH, Bachrach SJ, et al. Bone den-sitometry in pediatric patients treated with pamidronate. Pe-diatr Radiol 2005;35:511–17. 21.7 Sakkers R, Kok D, Engelbert R, et al. Skeletal effects andfunctional outcome with olpadronate in children with osteo-genesis imperfecta: a 2 year randomised placebo-controlledstudy. Lancet 2004;363:1427–31. 22.Grissom LE, Kecskemethy HH, Bachrach SJ, et al. Bone den-sitometry in pediatric patients treated with pamidronate. Pe-diatr Radiol 2005;35:511–17. 23.Munns CF, Rauch F, Zeitlin L, et al. Delayed osteotomy butnot fracture healing in pediatric osteogenesis imperfecta pa-tients receiving pamidronate. J Bone Miner Res2004;19:1779–86 24.Papapoulos SE, Cremers SCLM. Prolonged bisphosphonaterelease after treatment in children. N Engl J Med 2007;356:1075–76. 25.Ward KA, Adams JE, Freemont TJ, et al. Can bisphosphona-te treatment be stopped in a growing child with skeletal fra-gility? Osteoporos Int 2007;18:1137–40. 26.Bilezikian JP. Osteonecrosis of the jaw: do bisphosphonatespose a risk? N Engl J Med 2006;355:2278–81. 43 27.Whyte MP, Wenkert D, Clements KL, et al. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003;349:457–63.
There are 1 citations in total.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | makale |
| Authors | |
| Publication Date | January 21, 2018 |
| Published in Issue | Year 2018 Volume: 10 Issue: 1 |
